September Is Sickle Cell Awareness Month. While many people are familiar with sickle cell anemia, sickle cell traits have also plagued our community. Sickle cell trait (SCT) is an inherited blood ...

Pfizer (NYSE:PFE) has voluntarily withdrawn all lots of its sickle cell disease drug Oxbryta, also known as voxelotor, over safety concerns. The pharmaceutical giant said Oxbryta will be withdrawn ...

On Wednesday, Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where ...

(Bloomberg) -- European regulators suspended the approval of Pfizer Inc.’s sickle cell anemia drug, Oxbryta, citing a higher rate of disease complications in patients who started taking it.

Sickle cell disease (SCD) is an inherited disorder that affects over 100,000 people in the United States, according to the Sickle Cell Disease Association of America, of that number, the Centers ...

Conducted as part of the Sickle Cell Disease Implementation Consortium (SCDIC), the study included 2,282 individuals ages 15–45 years, with sickle cell disease. About 500 (22%) had HbSC.

Pfizer’s decision Wednesday to pull its sickle cell pill off the market because of safety concerns shocked advocates and doctors, leaving many searching for answers and scrambling for ways to ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 billion acquisition the New York pharma made two years ago. Pfizer will ...

Sept 26 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where it is approved, citing risks ...

Sept 19 (Reuters) - The State Bar of California’s plan to give its own bar exam starting in February hit a snag on Wednesday when the California Supreme Court denied its petition to make that ...

Pfizer said it is voluntarily withdrawing all lots of its sickle cell drug Oxbryta in all markets where it is approved, two years after acquiring its parent company Global Blood Therapeutic in a $ ...